OPT-80

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Diarrhea

Conditions

Diarrhea

Trial Timeline

Nov 1, 2004 → Apr 1, 2005

NCT ID

NCT00097422

About OPT-80

OPT-80 is a phase 2 stage product being developed by Merck for Diarrhea. The current trial status is completed. This product is registered under clinical trial identifier NCT00097422. Target conditions include Diarrhea.

What happened to similar drugs?

9 of 20 similar drugs in Diarrhea were approved

Approved (9) Terminated (4) Active (9)

✅loperamide-simethicone + matching placeboJohnson & JohnsonApproved

✅Loperamide/simeticone 2 mg/125 mg caplets + Loperamide/simeticone 2 mg/125 mg chewable tablets + Probiotic Saccharomyces boulardii 250 mg capsulesJohnson & JohnsonApproved

✅RV5 (Pentavalent Rotavirus Vaccine)MerckApproved

✅TEICOPLANINSanofiApproved

✅Bacillus Clausii Multi ATB Resist + PlaceboSanofiApproved

✅intravenous immunoglobulin G (IVIG) + PlaceboBayerApproved

✅Diosmectite (Smecta®)IpsenApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00097422	Phase 2	Completed	Nov 1, 2004	Apr 1, 2005	Diarrhea

Competing Products

20 competing products in Diarrhea

See all competitors

Product	Company	Stage	Hype Score
Metronidazole + Metronidazole-DRF1 + Metronidazole-DRF2	Dr. Reddy's Laboratories	Phase 2	32
YM060 + Placebo	Astellas Pharma	Phase 3	40
Fidaxomicin oral suspension + Fidaxomicin tablets + Vancomycin oral liquid + Vancomycin capsules	Astellas Pharma	Phase 3	40
YM060	Astellas Pharma	Phase 3	40
Ramosetron	Astellas Pharma	Pre-clinical	26
Racecadotril Film-Coated Tablet (FCT) + Racecadotril Capsule	Johnson & Johnson	Phase 1	29
loperamide-simethicone + matching placebo	Johnson & Johnson	Approved	43
Racecadotril + Racecadotril + Racecadotril + Racecadotril	Johnson & Johnson	Phase 1	29
Loperamide/simeticone 2 mg/125 mg caplets + Loperamide/simeticone 2 mg/125 mg chewable tablets + Probiotic Saccharomyces boulardii 250 mg capsules	Johnson & Johnson	Approved	43
fidaxomicin + Placebo	Merck	Phase 3	40
Surotomycin + Placebo	Merck	Phase 1	29
Surotomycin + Placebo	Merck	Phase 1	29
fidaxomicin	Merck	Phase 2	35
RV5 (Pentavalent Rotavirus Vaccine)	Merck	Approved	43
LJN452 + Placebo to LJN452	Novartis	Phase 2	35
Octreotide Long Acting Release	Novartis	Phase 3	40
DNK333 + Placebo	Novartis	Phase 2	35
Probiotic Supplement	Roche	Pre-clinical	26
Etrasimod + Placebo + Corticosteroids	Pfizer	Phase 2	27
Calcium Carbonate + nelfinavir + lamivudine + loperamide + nelfinavir + lamivudine + zidovudine	Pfizer	Phase 3	32